Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.72 |
| ▸ | CDK7 | P50613 | 2/20 | 0.68 |
| ▸ | CCNH | P51946 | 2/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 6/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | BLK | P51451 | 2/20 | 0.51 |
| ▸ | BMX | P51813 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17062815 | 0.90 | BTK (0.87) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL15640174 | 0.90 | BTK (0.89) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL17071652 | 0.88 | BTK (0.71) | BTKCDK7CCNHEGFRJAK3 | |
| SCHEMBL17071633 | 0.88 | BTK (0.73) | BTKCDK7CCNHEGFRJAK3 | |
| SCHEMBL17071472 | 0.88 | BTK (0.73) | BTKCDK7CCNHEGFRJAK3 | |
| SCHEMBL17071634 | 0.88 | BTK (0.70) | BTKCDK7CCNHEGFRJAK3 | |
| SCHEMBL17071642 | 0.87 | BTK (0.72) | BTKCDK7CCNHEGFRJAK3 | |
| SCHEMBL15639047 | 0.84 | BTK (0.68) | BTKCDK7CCNHCCNA2CDK2 | |
| SCHEMBL12813134 | 0.84 | BTK (1.00) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL15639959 | 0.83 | BTK (0.74) | BTKCDK7CCNHEGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3680238-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | University of Utah Research Foundation (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2018-05-17 | — | — | US | disclosed |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2018-05-17 | — | — | US | disclosed |
| US-9828376-B2 | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828376-B2 | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2015-09-10 | — | — | US | disclosed |
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2015-09-10 | — | — | US | disclosed |
| EP-2903972-A2 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | University Of Utah Research Foundation (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014055928-A2 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885CDK7 594/4885CCNH 2328/4885 |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885CDK7 571/4885CCNH 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.